![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Hadassah Medical Organization |
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00426322 |
The aim of this clinical study is to compare the amount of newly formed bone after bone augmentation with Bio-Oss® (BO) 0.25-1 mm vs. Bio-Oss® (BO) 1-2 mm in the sinus floor augmentation procedure bilaterally in 8 patients.
Hypothesis:
There is no difference in the relative amount of newly formed bone plus BO between the large (1-2 mm) and small (0.25 - 1 mm) granules.
Condition | Intervention |
Sinus Graft |
Device: bovine bone mineral particles (Bio-Oss®) |
MedlinePlus related topics: | Minerals |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | Efficacy of Sinus Floor Augmentation Using Large (1-2mm) or Small (0.25-1mm) Bovine Bone Mineral Particles (Bio-Oss®): A Comparative Histomorphometric Clinical Study |
Estimated Enrollment: | 8 |
Study Start Date: | March 2007 |
the use of bovine bone mineral particles (Bio-Oss®)in sinus floor augmentation is well established. bovine bone mineral is an oseoconductive material which serves as a space maintainer and a scaffold for bone augmentation. the commercial product is manufactured in two different particles sizes, "large"1-2 mm, and "small"0.25-1 mm.
Comparison: the histologic characteristics of augmented bone after the use of Bio-Oss® (BO) with particle size of 0.25-1 mm vs. Bio-Oss® (BO)with particle size of 1-2 mm.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lior Shapira, PhD | 00 972 2 6777826 | shapiral@cc.huji.ac.il |
Contact: Hadas Lemberg, PhD | 00 972 2 6777572 | lhadas@hadassah.org.il |
Israel | |||||
Hadassah Medical Organization | |||||
Jerusalem,, Israel |
Hadassah Medical Organization |
Principal Investigator: | Lior Shapira, PhD, DMD | department of periodontology, Hadassah Medical Organization |
Study Director: | Tali Chackartchi, DMD | department of periodontology,Hadassah Medical Organization |
Study ID Numbers: | shapiral-HMO-CTIL |
First Received: | January 23, 2007 |
Last Updated: | January 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00426322 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
![]() |